Onyx Pharmaceuticals, Inc.'s Drug Candidates Might Attract Acquirers, CFO Says
Published: Jan 16, 2012
Onyx Pharmaceuticals Inc., (ONXX) the developer of kidney cancer drug Nexavar, is an attractive target for acquirers because it may receive regulatory approvals for several new treatments during the next year, Chief Financial Officer Matt Fust said. Onyx was labeled the top biotechnology takeover target in 2012 in a survey last week by Mark Schoenebaum, an analyst with ISI Group in New York. The South San Francisco, California-based company was exploring options, including a potential sale process last year, two people familiar with the situation said in November.